User experience with an oral contraceptive containing ethinylestradiol 30μg and drospirenone 3mg (yasmin®) in clinical practice

Treatments in Endocrinology

Volumn 5, Issue 4, 2006, Pages 251-256

  Schultz Zehden, Beate ^a   Boschitsch, Ewald ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Ambulatorium Klimax   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL SWELLING; ADULT; ARTICLE; BLOATING; BREAST TENDERNESS; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; FAMILY PLANNING; FEMALE; GENERAL PRACTITIONER; GYNECOLOGY; HAIR DISEASE; HUMAN; IRRITABILITY; MASTALGIA; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUESTIONNAIRE; SATISFACTION; SKIN DISEASE; WEIGHT CHANGE; CONTRACEPTION; EUROPE;

CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; EUROPE; HUMANS; SURVEYS AND QUESTIONNAIRES;

EID: 33746676870     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605040-00006     Document Type: Article

References (19)

1. Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9 (2): 57-68
2. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995 May; 40 (5): 355-60
3. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577-82
4. Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. New York: Raven Press Ltd, 1991
5. Potter L, Oakley D, de Leon-Wong E, et al. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996; 28 (4): 154-8
6. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30 (2): 89-92, 104
7. Heinemann LA, Thiel C, Assmann A, et al. Frequency and reasons for switching/stopping use of oral contraceptives: results of the German Cohort Study on Women Health. Zentralbl Gynakol 2001; 123 (10): 568-77
8. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000 Jul; 62 (1): 29-38
9. Foidart J-M, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5 (2): 124-34
10. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25-34
11. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61 (2): 105-11
12. Thorneycroft IH, Gollnick H, Schellschmidt I. Superiority of a combined oral contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74: 123-30
13. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69 Suppl. 4: 2-15
14. Medical Outcomes Trust and QualityMetric Incorporated. SF-36 health survey [online]. Available from URL: http://www.sf-36.org/tools/pdf/SF- 36v1_Standard_Sample.pdf [Accessed 2006 Apr 11]
15. Poindexter AN, Burkman R, Fisher AC, et al. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. Int J Fertil Womens Med 2003; 48 (4): 163-72
16. Sulak P, Lippman J, Siu C, et al. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol: cycle control, lipid effects, and user satisfaction. Contraception 1999; 59 (3): 161-6
17. Boschitsch E, Skarabis H, Wuttke W, et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000; 5 Suppl. 3: 34-40
18. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10 (6): 561-9
19. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on perimenstrual symptoms. J Reprod Med 2002; 47 (1): 14-22